• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elutia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    3/4/26 8:00:18 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email
    ELUTIA INC._March 4, 2026
    0001708527false00017085272026-03-042026-03-04

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): March 4, 2026

    ​

    ELUTIA INC.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    Delaware

    001-39577

    47-4790334

    (State or other jurisdiction
    of incorporation)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    ​

    20 Firstfield Road

    Gaithersburg, MD 20878

    (Address of principal executive offices) (Zip Code)

    ​

    (240) 247-1170

    (Registrant’s telephone number, include area code)

    ​

    N/A

    (Former name or former address, if changed since last report)

    ​

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

    ​

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    ​

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

      ​ ​ ​

    Trading Symbols

      ​ ​ ​

    Name of each exchange
    on which registered

    Class A Common Stock, $0.001 par value per share

     

    ELUT

     

    The Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 8.01

    Other Events.

    As previously reported, on November 7, 2025, Elutia Inc., a Delaware corporation (the “Company” or “Elutia”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

    ​

    Also, as previously reported, on December 23, 2025, the Company received a letter from the Staff of Nasdaq, notifying the Company that it was not in compliance with the continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities (“MVLS”) of at least $35 million (the “MVLS Requirement”). Based on the Staff’s review of the Company’s MVLS, the Company’s MVLS was below $35 million for the previous 30 consecutive business days. The letter also noted that the Company does not meet the additional requirements under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3) relating to minimum shareholder equity or net income standards.

    ​

    On February 5, 2026, the Company received a letter from Nasdaq, notifying the Company that the Staff has determined that it has regained compliance with the MVLS Requirement as a result of the Company’s MVLS being $35 million or greater for the eleven consecutive business days from January 21, 2026 through February 4, 2026. Accordingly, the letter indicated that the Company is in compliance with the MVLS Requirement, and the matter is closed.

    ​

    On March 2, 2026, the Company received a letter from Nasdaq, notifying the Company that the Staff has determined that is has regained compliance with the Minimum Bid Price Requirement as a result of the closing bid price of the Common Stock being at $1.00 per share or greater for the 10 consecutive business days from February 13, 2026 through February 27, 2026. Accordingly, the letter indicated that the Company is in compliance with the Minimum Bid Price Requirement, and the matter is closed.

    ​

    On March 4, 2026, the Company issued a press release announcing that the Company has regained compliance with the Minimum Bid Price Requirement and the MVLS Requirement. A copy of the press release is attached hereto as Exhibit 99.1.

    ​

    Item 9.01

    Financial Statements and Exhibits.

    (d)

    Exhibits.

    Exhibit No.

    ​

    Exhibit Description

    ​

    ​

    ​

    99.1

    ​

    Press Release of Elutia Inc., dated March 4, 2026

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (formatted as Inline XBRL document)

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

     

    ELUTIA INC.

     

     

     

    Date: March 4, 2026

    By:

    /s/ Matthew Ferguson

     

     

    Matthew Ferguson

     

     

    Chief Financial Officer

    ​

    ​

    Get the next $ELUT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elutia Regains Compliance with Nasdaq Listing Requirements

    GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Marke

    3/4/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    SEC Filings

    View All

    Elutia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ELUTIA INC. (0001708527) (Filer)

    3/4/26 8:00:18 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

    SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/17/26 4:36:43 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

    SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/13/26 5:05:45 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

    Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company's Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels' appointment, W. Matthew Zuga and Maybelle Jordan have both stepped down as members of Elutia's Board. "Randy and I are excited to welcome Guido to our Board of Directors and the Elutia CRU," said Kevin Rakin, Executive Chairman of Elutia. "G

    10/10/25 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Financials

    Live finance-specific insights

    View All

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

    - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioEnvelope Business Sold to Boston Scientific Corporation for $88 Million: Transaction closed October 1, 2025, with proceeds used to eliminate debt and fund NXT-41x development program.Advancing Nex

    11/6/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    10/23/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elutia Inc.

    SC 13G - ELUTIA INC. (0001708527) (Subject)

    10/15/24 6:59:31 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

    SC 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/20/24 12:03:03 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care